A b s t r a c t
Several studies have shown that glypican 3 (GPC3) could be a useful diagnostic marker for hepatocellular carcinoma (HCC) and for differentiating HCC from nonneoplastic and preneoplastic liver disease. To systematically investigate the epidemiology of GPC3 expression in the liver and in other organs and tissues, we used tissue microarray technology comprising 4,387 tissue samples from 139 tumor categories and 36 nonneoplastic and preneoplastic tissue types.
The immunohistochemical expression of GPC3 was assessed semiquantitatively using a 10% cutoff score and was detected in 9.2% of nonneoplastic liver samples (11/119) , 16% of preneoplastic nodular liver lesions (6/38) (27/50 [54%] ), testicular nonseminomatous germ cell tumors (32/62 [52%] ), and liposarcoma (15/29 [52%] ).
Glypicans are a family of heparan sulfate proteoglycans that bind to the exocytoplasmic surface of the plasma membrane by a glycosyl-phosphatidylinositol anchor. 1,2 By using their heparan sulfate chains, they are known to stimulate or inhibit growth factor activity and thereby to take over the coreceptor function for heparin-binding growth factors. Because glypicans are predominantly expressed during development in a cell-and tissue-specific manner, a crucial role in morphogenesis is assumed. 1, 3 Up to now, 6 members of the glypican gene family (GPC1-GPC6) have been identified in mammals. 4 Glypican 3 (GPC3) was first identified in patients with Simpson-Golabi-Behmel syndrome, a rare X-linked disorder characterized by prenatal and postnatal overgrowth caused by mutation of the GPC3 gene. 5, 6 Further studies underlined the important role of GPC3 in regulation of cell proliferation and apoptosis during normal development. 7 In several malignant tumors, including ovarian carcinoma, cholangiocarcinoma, mesothelioma, and breast cancer, GPC3 is down-regulated as a result of hypermethylation of the GPC3 promoter. [8] [9] [10] [11] Because the GPC3 protein product is highly expressed in normal ovarian, mammary, and mesothelial cells, GPC3 has been considered a tumor suppressor gene in these organs. [10] [11] [12] In contrast, other malignant tumors such as hepatocellular carcinoma (HCC), embryonal tumors, and colon cancer were shown to highly express GPC3 compared with the corresponding normal tissue. [13] [14] [15] [16] The function of GPC3, therefore, seems to differ in a tissue-dependent manner, displaying apoptosis-inducing properties in the ovary and in the breast and oncofetal protein-like characteristics in the liver and in embryonal tumors.
GPC3 expression was recently shown to be markedly elevated in a large proportion of HCCs, whereas preneoplastic and nonneoplastic liver tissue samples revealed less frequent and no GPC3 expression, respectively. 8, [16] [17] [18] [19] Therefore, GPC3 seems to be of diagnostic use in differentiating preneoplastic and well-differentiated neoplastic hepatocellular disorders and might represent a specific tumor marker for HCC. To study the specificity of GPC3 and its potential use as a diagnostic marker in the liver and in other organs and tissue types, we performed immunohistochemical analyses on a multitumor array (MTA) containing 3,916 tissue samples from 139 tumor categories and 31 normal human tissue types. Furthermore, 377 samples of nonneoplastic, preneoplastic, and neoplastic liver disorders and 94 samples of cholangiocellular carcinoma (CCC) and normal biliary tract mucosa were analyzed using additional tissue microarrays (TMAs; liver carcinogenesis and cholangiocarcinoma array).
Materials and Methods

MTA Tissue Samples
A preexisting set of TMAs with 3,916 tissue samples was selected for the study. 20 23 respectively. , In the remaining cases of HCC, the amount of paraffin-embedded tissue was insufficient for appropriate grading.
CCC Array Tissue Samples
This array contained evaluable tissue samples of 24 intrahepatic, 44 extrahepatic cholangiocellular, and 8 gallbladder carcinomas, and 18 samples of normal biliary tract mucosa. All tissue samples were retrieved from the archives of the Institute of Pathology, University of Bern, Bern, Switzerland, and were reviewed by an experienced pathologist (E.K.D).
Tissue Microarray
Tissue samples were fixed in buffered 4% formalin, embedded in paraffin, and used to construct a TMA. Briefly, H&E-stained sections were made from each selected primary block (donor blocks) to define representative tissue regions. Tissue cylinders (0.6 mm in diameter) were then punched from the region of the donor block with the use of a custom-made precision instrument (Beecher Instruments, Silver Spring, MD). Tissue cylinders were transferred to a 25 × 35 mm paraffin block to produce the TMA block used for the study. The resulting TMA block was cut into 3-µm sections that were transferred to glass slides by use of the Paraffin Sectioning Aid System (Instrumedics, Hackensack, NJ). Sections from the TMA block were used for immunohistochemical analysis.
Immunohistochemical Analysis
For immunohistochemical analysis, 3-µm sections of the TMA blocks were deparaffinized in xylene and rehydrated afterward. Endogenous peroxidase activity was blocked by using 0.3% hydrogen peroxide in methanol for 30 minutes. Sections were heated in citrate buffer (pH 6.0) for 30 minutes in a water bath at 98.5°C and subsequently incubated with a monoclonal anti-GPC3 antibody (clone 1G12, dilution 1:100; BioMosaics, Burlington, VT) for 20 minutes at room temperature. Thereafter, incubation with an antimouse peroxidase-conjugated EnVision antibody (DAKO, Baar, Switzerland) was conducted for 30 minutes at room temperature. The reaction product was developed using 3,39-diaminobenzidine tetrahydrochloride and hydrogen peroxide, and the sections were counterstained with hematoxylin. The negative control samples were prepared by omitting the primary antibody.
Immunoreactivity for GPC3 was scored semiquantitatively by evaluating the number of positive tumor cells over the total number of tumor cells. Scores were assigned using 5% intervals and ranged from 0% to 100%. The reproducibility of this scoring method between pathologists has been demonstrated for TMAs. 24, 25 According to the score suggested by Yamauchi et al, 19 the cutoff score for tumor positivity and negativity was determined at 10%.
Statistical Evaluation
The χ 2 test with Pearson correction was used as appropriate. A P value of less than .05 was considered significant. Calculations were performed with JMP software (SAS Institute, Cary, NC).
Results
Glypican 3 expression could be evaluated in 94.5% of 4,387 tissue samples. The reason for analysis failure was related to TMA technology, including fractions of missing samples or samples containing only a few tumor cells.
MTA Results for Normal Tissue Samples
In normal tissue samples, only gastric glands (3/7 [43%]), kidney tubules (9/17 [53%]), and testicular germ cells (2/16 [13%]) stained positively for GPC3. No GPC3 staining was found in the following tissue types: breast, brain (gray and white matter), colon (mucosa), esophagus, fat tissue, gallbladder, heart, liver, lung, lymph nodes, mouth (mucosa), ovary, pancreas, parathyroid, parotid gland, prostate, skeletal muscle, skin, small intestine (mucosa), smooth muscle, submandibular gland, thymus, thyroid, urinary bladder, and uterus (cervix, endometrium, and myometrium). 
MTA Results for Tumors
squamous cell carcinoma of the lung, testicular nonseminomatous germ cell tumors, liposarcoma, cervical intraepithelial neoplasia grade 3, melanoma, and schwannoma, also revealed consistent expression of GPC3. It is interesting that none of these tumors showed hepatoid differentiation. zTable 2z and zTable 3z list all tumor categories demonstrating infrequent or no expression of GPC3.
Liver Carcinogenesis Array
Nonneoplastic liver tissue, preneoplastic nodular liver lesions, and HCCs revealed GPC3 expression in 11 (9.2%) of 119, 6 (16%) of 38, and 140 (63.6%) of 220 samples, respectively (P < .0001) zTable 4z. The 11 cases of liver cirrhosis demonstrating GPC3 expression were HBV+ in 7 cases, HCV+ in 1 case, and HBV+/HCV+ in 1 case. In the remaining 2 cases, liver cirrhosis was of unknown cause.
CCC Array
CCCs (intrahepatic and extrahepatic), gallbladder carcinomas, and normal biliary tract mucosa demonstrated GPC3 expression in 3 (13%) of 24, 4 (9%) of 44, 1 (13%) of 8, and 3 (17%) of 18 samples, respectively zTable 5z. 
Discussion
Knowledge about the expression of GPC3 in normal and neoplastic tissues evolved in a manner similar to that for antibodies proposed as diagnostic tools for the distinction of different tumor entities and for nonneoplastic, preneoplastic, and neoplastic disorders. After initial reports have provided evidence and sensitivity for diagnostic usefulness, other studies subsequently demonstrate the expression of the concerned biomarker in various additional tumor and tissue types. TMAs are an ideal tool to characterize novel biomarkers in a fast and effective manner. Several studies have proven TMAs to provide reliable and representative data. 20, 21, [26] [27] [28] [29] GPC3 was found to be frequently expressed in HCCs and, therefore, to possibly function as a diagnostic marker. 8, [16] [17] [18] [19] In our series, HCCs showed the most frequent GPC3 expression of 139 tumor entities studied (MTA, 29/44 [66%]; liver carcinogenesis array, 140/220 [63.6%]). In previous studies, however, GPC3 expression in HCC ranged between 72% and 90% immunohistochemically or immunocytochemically, whereas elevated messenger RNA levels were detected even more frequently. 8, [16] [17] [18] [19] [30] [31] [32] The reason for the slightly lower sensitivity of GPC3 expression in our series cannot be explained unequivocally. The extent of GPC3 immunoreactivity can be affected by the tumor grade because less differentiated HCCs were shown to have a greater number of immunoreactive cells. 32 In our liver carcinogenesis array, well-and moderately differentiated HCCs (G1 and G2) constituted 68.6% of all HCC samples, but the poorly differentiated tumors included (G3 and G4) demonstrated, in contrast to the literature, less frequent GPC3 expression. GPC3 expression in preneoplastic nodular liver lesions was detected in 6 (16%) of 38 cases and was restricted to high-grade dysplastic nodules only. Yamauchi and colleagues 19 demonstrated a higher incidence of GPC3 expression in dysplastic nodules (2/8 low-grade and 6/8 high-grade nodules), whereas Di Tommaso and colleagues 32 found a lower incidence (0/15 low-grade and 2/22 high-grade nodules). Owing to the small number of cases studied, only limited conclusions can be drawn, but at least there was a trend toward higher GPC3 expression in high-grade compared with low-grade dysplastic nodules. Surprisingly, we detected GPC3 expression in 11 (9.2%) of 119 nonneoplastic liver samples. All positive samples were derived from cirrhotic livers and were almost exclusively HBV+ (8/11 [73%] ). Recently, GPC3 expression was reported in 84% of chronic hepatitis C samples with high-grade activity. 33 GPC3 expression, therefore, does not seem to be restricted to preneoplastic or neoplastic liver disease. However, our study demonstrated a gradient of GPC3 expression in nonneoplastic (9.2%), preneoplastic (16%), and neoplastic (63.6%) liver tissue samples (P < .0001) and, therefore, underlines the role of GPC3 in hepatocarcinogenesis.
CCCs and gallbladder carcinomas demonstrated GPC3 expression in 8 (11%) of 76 cases. Yamauchi and colleagues 19 found no GPC3 expression in CCCs, but they studied a smaller series with only 16 cases. Our data, however, indicate only very limited use of GPC3 in the differential diagnosis of CCC and several other metastatic tumors that can be mistaken for HCC because several of these tumors demonstrated equal frequencies of GPC3 expression (eg, adenocarcinoma of the stomach, 20%; transitional cell carcinoma, 16%; adenocarcinoma of the lung, 10%; and invasive ductal carcinoma of the breast, 8%).
The consistent expression of GPC3 in testicular nonseminomatous germ cell tumors was reported only recently, 34 whereas in squamous cell carcinoma of the lung and in liposarcoma, it had never been described before zImage 1z. In human breast cancer, GPC3 was shown to be silenced due to hypermethylation of the GPC3 promoter. 9, 12 In our study, lobular and medullary carcinoma of the breast demonstrated GPC3 expression in 20% and 17%, respectively, whereas ductal carcinoma demonstrated GPC3 positivity in only 8% of the cases studied. Silencing of GPC3 could, therefore, be a characteristic event in certain subgroups of breast cancers. Several other studies reported GPC3 to be a promising diagnostic marker in melanoma. [35] [36] [37] Most studies, however, investigated GPC3 as a serum marker, with only 1 series demonstrating GPC3 expression in 17 (81%) of 21 samples immunohistochemically. 37 We found expression of GPC3 in 14 (29%) of 48 melanomas included in our MTA. Our data confirm that GPC3 is highly expressed in HCC. The sensitivity of only 64.0% (169/264) suggests a rather limited impact of GPC3 as the sole diagnostic marker in the differential diagnosis of neoplastic hepatic nodules. We therefore recommend the use of GPC3 as part of an immunohistochemical panel. As shown only recently, combined expression of GPC3, HSP70, and glutamine synthetase reached sensitivity and specificity of 72% and 100%, respectively, in differentiating early and well-differentiated HCC from preneoplastic nodular liver lesions. 32 Furthermore, our study shows immunohistochemical GPC3 positivity in several other tumor entities for the first time. These findings should be kept in mind in the histologic evaluation of primary and metastatic liver tumors.
From the 1 ) . B, High-grade grade dysplastic nodule of the liver (H&E, ×400). C-F, Strong glypican 3 expression in the 4 most consistently glypican 3-expressing tumors of our series: hepatocellular carcinoma (C, ×400), nonseminomatous germ cell tumor (D, ×400), squamous cell carcinoma of the lung (E, ×400), and liposarcoma (F, ×400).
